3 Top Quality Value Stocks To Watch In October 2026
Yahoo · 14 de oct de 2026
Rising gasoline and diesel costs are pushing US inflation higher, and that puts steady cash generation and conservative balance sheets back in the spotlight. Wh…
CEDEAR VRTX
VERTEX PHARMACEUTICALS INC
Sí, existe CEDEAR de VRTX en Argentina. Operás bajo el ticker VRTX en BYMA, con ratio 101:1 respecto a la acción en NYSE.
Empresa subyacente
HealthcareBiotechnology
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
- País
- United States
- Empleados
- 6.400
- Sitio web
- vrtx.com
Precio histórico
No hay suficientes datos históricos para mostrar el gráfico de VRTX.
Cotización y datos
NYSERatio 101:1 · Subyacente VRTX
CEDEAR (ARS)
Precio
$ 8.200
Var. %
+2,37%
Volumen operado
980
Subyacente (USD)
Precio VRTX
US$ 510,90
Teórico (precio / ratio)
VRTX ÷ 101
US$ 5,06
Dólar MEP (VRTXD)
Preguntas frecuentes
¿Existe CEDEAR de VRTX en Argentina?
Sí, existe el CEDEAR de VRTX (VERTEX PHARMACEUTICALS INC) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es VRTX.
¿Cuál es el ticker del CEDEAR de VERTEX PHARMACEUTICALS INC?
El ticker del CEDEAR de VERTEX PHARMACEUTICALS INC en Argentina es VRTX. La acción subyacente cotiza en NYSE con el símbolo VRTX.
¿Cuál es el ratio del CEDEAR VRTX?
El CEDEAR VRTX tiene un ratio de 101:1. Eso significa que 101 CEDEARs equivalen a 1 acción de VRTX.
¿Cuánto vale el CEDEAR VRTX hoy?
El CEDEAR VRTX cotiza hoy a $ 8.200 en pesos argentinos, con una variación diaria de +2,37%.
¿Cuánto vale la acción VRTX en dólares?
Noticias
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo · 13 de oct de 2026
Vertex raised its full-year outlook in Q2 with a growing pipeline across multiple disease areas. Moderna’s mRNA flu vaccine just cleared a key FDA hurdle with a…
2 High-Flying Stocks on Our Watchlist and 1 We Question
Yahoo · 12 de oct de 2026
“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the pre…
